维生素D的两个阈值水平与三级医院门诊患者合并症患病率
该横断面研究纳入529例门诊患者,按25OHD水平分为G1组(≥20且<30 ng/mL)和G2组(≥30且≤50 ng/mL),比较合并症数量。G1组合并症数量更高,包括血糖异常、血脂异常、关节病、贫血等。作者认为对该人群25OHD≥30 ng/mL可能更合适。
要点
- 25OHD≥20且<30 ng/mL组比≥30 ng/mL组合并症数量更高
- G2组骨质疏松和甲状腺功能减退更常见
- 贫血、关节病、神经精神疾病与25OHD分组独立相关
核心结论
- 血清25OHD≥20且<30 ng/mL的患者比≥30 ng/mL的患者合并症患病率更高。
研究设计与样本
- 横断面研究,纳入三级医院门诊患者529例,测量1年内的25OHD,排除25OHD<20和>50 ng/mL者、临床研究参与者、肝病患者和慢性肾衰竭患者。
主要发现
- G1组319例(平均年龄53.3±15.8岁,女性85%),平均25OHD 24.8±2.8 ng/mL;G2组210例(平均年龄56.7±16.0岁,女性83%),平均25OHD 36.8±4.8 ng/mL。
- G1组合并症数量更高,包括血糖异常、血脂异常、甲状腺功能减退、泌尿系统疾病、关节病、继发性甲状旁腺功能亢进、贫血、神经和精神疾病。
- G2组骨质疏松和甲状腺功能减退更常见。
- 二元logistic回归显示年龄(OR 0.988,CI 0.97-1.00,p=0.048)、骨质疏松(OR 0.54,CI 0.36-0.80,p=0.003)、血脂异常(OR 1.61,CI 1.10-2.39,p=0.015)、关节病(OR 2.60,CI 1.40-5.10,p=0.003)、贫血(OR 15.41,CI 3.09-280.08,p=0.008)、神经和精神疾病(OR 3.78,CI 1.98-7.88,p=0.001)保持显著。
关键数值与推荐
- G1组25OHD≥20且<30 ng/mL,G2组25OHD≥30且≤50 ng/mL。
- 二元logistic回归中贫血OR 15.41(CI 3.09-280.08,p=0.008),神经和精神疾病OR 3.78(CI 1.98-7.88,p=0.001),关节病OR 2.60(CI 1.40-5.10,p=0.003)。
临床怎么用
- 作者认为对该特定人群,25OHD≥30 ng/mL可能更合适。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: This study evaluated the number of comorbidities between two normal values of 25OHD in outpatients during 1 year of 25OHD measurements. Five hundred twenty-nine outpatients were included, patients with 25OHD ≥ 20 and < 30 ng/mL had the higher number of comorbidities, suggesting that for this specific population, 25OHD ≥ 30 ng/mL would be more appropriate. INTRODUCTION : This study evaluated the comorbidities between two values of 25OHD in outpatients of a tertiary hospital. METHODS: This is a cross-sectional study with measures of 25OHD in 1-year period, excluding 25OHD < 20 and > 50 ng/mL, clinical research participants, and liver disease and chronic renal failure patients. Patients were divided into two groups: group 1 (G1), 25OHD ≥ 20 and < 30 ng/mL; and group 2 (G2), 250HD ≥ 30 and ≤ 50 ng/mL. Medical records were reviewed for demographic, laboratory, and comorbidity data. RESULTS: From 529 outpatients included, 319 were in G1 (53.3 ± 15.8 years, 85% women), mean 25OHD 24.8 ± 2.8 ng/mL; and 210 outpatients in G2 (56.7 ± 16.0 years, 83% women), mean 25OHD was 36.8 ± 4.8 ng/mL. G1 had the higher number of comorbidities, including altered glycemia, dyslipidemia, hypothyroidism, urinary tract diseases, arthropathy, secondary hyperparathyroidism, anemia, and neurological and psychiatric disorders. Osteoporosis and hypothyroidism were more prevalent in G2. After binary logistic regression, the variables age (OR 0.988, CI 0.97-1.00, p = 0.048), osteoporosis (OR 0.54, CI 0.36-0.80, p = 0.003), dyslipidemia (OR 1.61, CI 1.10-2.39, p = 0.015), arthropathy (OR 2.60, CI 1.40-5.10, p = 0.003), anemia (OR 15.41, CI 3.09-280.08, p = 0.008), and neurological and psychiatric diseases (OR 3.78, CI 1.98-7.88, p = 0.001) maintained significance. CONCLUSION: Patients with serum 25OHD ≥ 20 and < 30 ng/mL had higher prevalence of comorbidities compared to ≥ 30 ng/mL.
引用
- Furuie IN, Mauro MJJ, Petruzziello S, et al. Two threshold levels of vitamin D and the prevalence of comorbidities in outpatients of a tertiary hospital. Osteoporos Int. 2017. PMID: 29143130. doi:10.1007/s00198-017-4299-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。